BioMedSA’s Board of Directors approved 2 new memberships in April 2026: Bartlett Cocke General Contractors and Cizzle Bio.
Bartlett Cocke General Contractors is a Texas‑based construction firm recognized for its extensive work in healthcare and clinical environments. The company has delivered a wide range of medical facilities, including hospitals, imaging centers, surgical suites, and specialized treatment spaces that support advanced biomedical equipment and regulatory requirements. Their experience includes building MRI and CT suites, nuclear medicine labs, and other precision‑controlled environments essential to modern diagnostics and patient care. Through this work, Bartlett Cocke contributes to the infrastructure that enables biomedical innovation, clinical research, and high‑quality healthcare delivery across the region.
Cizzle Bio develops biomarker‑based blood tests aimed at improving early cancer detection. The company’s work currently focuses on lung and gastric cancers, including tests built around the CIZ1B biomarker and the DEX‑G2 gastric cancer assay. These tests are designed to offer minimally invasive options for identifying disease earlier in the clinical pathway. Through this approach, Cizzle Bio seeks to contribute to ongoing efforts to enhance diagnostic accuracy and support timely clinical decision‑making.